ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET
Company Participants
Joe Burnett - Chief Executive Officer
Danilo D’Alessandro - Chief Financial Officer
Conference Call Participants
Frank Takkinen - Lake Street Capital
William Wood - B. Riley
Operator
Greetings, and welcome to the ClearPoint Neuro Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this call is being recorded.
Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the Company's plans, prospects and strategies, both preliminary and projected and management's expectations, beliefs, estimates or projections regarding future results of operations. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events.
For more information, please refer to the Company's annual report on Form 10-K for the year-ended December 31, 2021 and the company's quarterly report on Form 10-Q for the first three months ended March 31, 2022, both of which have been filed with the Securities and Exchange Commission and the company's quarterly report on Form 10-Q for the three months ended June 30 2022, which the company intends to file with the Securities and Exchange Commission on or before August 15, 2022. All the company's filings may be obtained from the SEC or the company's website at www.clearpointneuro.com.
I would now like to turn the conference over to your host Joe Burnett, Chief Executive Officer.
Joe Burnett
Good afternoon everyone, and thank you to all of the investors and analysts on today's call for being a part of the ClearPoint vision and journey. Our mission and our priority is to help restore quality of life to patients and their families, who are suffering from some of the most debilitating neurological disorders imaginable.
In the first half of 2022, we continue to make progress across our four-pillar growth strategy, including biologics and drug delivery, functional neurosurgery navigation, therapy and access products and in achieving global scale. Despite a continued high cancellation of procedures due to COVID, historically high surgeon transitions and daily supply chain challenges, our team was able to achieve record revenue of $5.2 million for the second quarter, representing 52% growth year-over-year.